VISION Trail Results Indicate Benefit of ¹⁷⁷Lu-PSMA-617A Added to Standard Therapy, Cancer Network, Jason M. Broderick, June 3, 2021

A 40% reduction in the risk of death was observed when ¹⁷⁷Lu-PSMA-617A was added to standard of care therapy in patients with PSMA-positive metastatic castration-resistant prostate cancer. Read the article >>